Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies

BACKGROUND: Myelofibrosis (MF)‐associated constitutional symptoms can severely impact health‐related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction ≥50% from baseline. However, this dichotomous...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesa, Ruben A., Hudgens, Stacie, Floden, Lysbeth, Harrison, Claire N., Palmer, Jeanne, Gupta, Vikas, McLornan, Donal P., McMullin, Mary F., Kiladjian, Jean‐Jaques, Foltz, Lynda, Platzbecker, Uwe, Fox, M. Laura, Mead, Adam J., Ross, David M., Oh, Stephen T., Perkins, Andrew, Leahy, Michael F., Deheshi, Samineh, Donahue, Rafe, Klencke, Barbara J., Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225216/
https://www.ncbi.nlm.nih.gov/pubmed/37021939
http://dx.doi.org/10.1002/cam4.5799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225216/
https://www.ncbi.nlm.nih.gov/pubmed/37021939
http://dx.doi.org/10.1002/cam4.5799

Ejemplares similares